| Pharmacometrics in Academia: Role for Clinical Researches and Dissemination to Industry in KoreaClinical Therapeutics |
| Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate DecisionsNeoplasia |
| Hydrochlorothiazide does not increase furosemide's effects in end-stage renal diseaseTranslational and Clinical Pharmacology |
| Development and validation of analytical method for the determination of radotinib in human plasma using liquid chromatography-tandem mass spectrometryTranslational and Clinical Pharmacology |
| Principles of transparency and clinical trial registrationTranslational and Clinical Pharmacology |
| Tutorial for beginners: the concept of clearance explained using the example of a vacuum cleanerTranslational and Clinical Pharmacology |
| Drug-drug interaction of microdose and regular-dose omeprazole with a CYp2C19 inhibitor and inducerDrug design, development and therapy |
| Development of an automated appendix generation system (ARGUS) for clinical study reportsTranslational and Clinical Pharmacology |
| Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysisTranslational and Clinical Pharmacology |
| a 6-month mixed-effect pharmacokinetic model for post-transplant intravenous anti-hepatitis B immunoglobulin prophylaxisDrug Design, Development and Therapy |
| Human microdosing and mice xenograft data of AGM-130 applied to estimate efficacious doses in patientsCancer chemotherapy and pharmacology |
| Use of a Target?Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC 1118, an Anti?epidermal Growth Factor Receptor AntibodyBasic & clinical pharmacology & toxicology |
| Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapyAnti-cancer drugs |